

REMARKS

The following is in response to a restriction requirement dated November 26, 2007. The Office requires election between the following groups:

Group I: Claims 1-15, 17-18 and 22-24 drawn to compounds, compositions and methods of use of compounds of formula (I)

Group II, Claim(s) 30, drawn to compounds of formula (II)

Group III, Claim(s) 31, drawn to compounds of formula (III)

Group IV, Claim(s) 32, drawn to compounds of formula (IV)

Group V, Claim(s) 33, drawn to compounds of formula (X)

Group VI, Claim(s) 34, drawn to compounds of formula (XIX)

Group VII, Claim(s) 20, drawn to a process of making compounds of formula (I)

Group VIII, Claim(s) 25, drawn to a process of making compounds of formula (I)

Group IX, Claim(s) 26, drawn to a process of making compounds of formula (I)

Group X, Claim(s) 27, drawn to a process of making compounds of formula (I)

Group XI, Claim(s) 28, drawn to a process of making compounds of formula (I)

Group XII, Claim(s) 29, drawn to a process of making compounds of formula (I)

Applicants elect the claims of Group I, i.e., Claims 1-15, 17-18 and 22-24 without traverse. Such claims are elected without traverse since it is believed that these claims are patentably distinct from the claims of Groups II through XII.

The Office also requests an election of species if any of Groups I through VII are elected. Applicants hereby elect the species 4- $\{(1R)-2-[(6-\{4-[3-(cyclopentylsulfonyl)phenyl]butoxy\}hexyl)amino]-1-hydroxyethyl\}-2-(hydroxymethyl)phenol$. Currently, it is believed that Claims 1-15, 17-18 and 24 are readable on the species. Claims 20 and 25-34 are canceled, and Claims 2, 10 and 13 are amended to better conform their content to US practice.

Substantive examination on the merits is respectfully requested. No fees are believed to be due in connection with this submission. Nonetheless, the Office is authorized to charge any necessary fees, or credit any overpayment, to Deposit Account No. 07-1392.

Respectfully submitted,

/Robert J. Smith/
Robert J. Smith
Attorney for Applicant
Registration No. 40,820

Date: December 11, 2007
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-9616
Facsimile: 919-483-7988